Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 3,145,000 | 3,434,300 | 3,362,700 | 3,158,100 | 3,162,100 |
| Cost of Goods | 433,800 | 517,000 | 436,400 | 404,900 | 457,500 |
| Gross Profit | 2,711,200 | 2,917,300 | 2,926,300 | 2,753,200 | 2,704,600 |
| Operating Expenses | 1,960,600 | 1,945,400 | 1,815,700 | 1,737,600 | 1,758,400 |
| Operating Income | 751,400 | 972,900 | 1,111,000 | 1,016,500 | 946,700 |
| Interest Expense | 16,100 | 18,300 | 17,800 | 18,900 | 18,000 |
| Other Income | -34,600 | 193,000 | 17,600 | 85,300 | -70,700 |
| Pre-tax Income | 700,700 | 1,147,600 | 1,110,800 | 1,082,900 | 858,000 |
| Income Tax | -21,300 | -12,000 | 103,000 | 114,500 | 40,200 |
| Net Income Continuous | 722,000 | 1,159,600 | 1,007,800 | 968,400 | 817,800 |
| Net Income | $722,000 | $1,159,600 | $1,007,800 | $968,400 | $817,800 |
| EPS Basic Total Ops | 6.70 | 10.88 | 9.48 | 9.05 | 7.64 |
| EPS Basic Continuous Ops | 6.70 | 10.89 | 9.48 | 9.05 | 7.64 |
| EPS Diluted Total Ops | 6.27 | 10.21 | 8.89 | 8.50 | 7.17 |
| EPS Diluted Continuous Ops | 6.27 | 10.21 | 8.89 | 8.50 | 7.17 |
| EPS Diluted Before Non-Recurring Items | 7.97 | 10.18 | 10.17 | 8.79 | 8.44 |
| EBITDA(a) | $865,500 | $1,085,899 | $1,216,400 | $1,119,600 | $1,046,200 |